Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 607 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bone Development Clear all
Enrolling by invitation Phase 2 Interventional

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

NCT05796440
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
LUM-201
Drug
Lead sponsor
Lumos Pharma
Industry
Eligibility
5 Years to 14 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Iowa City, Iowa • Worcester, Massachusetts • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 29, 2026, 5:07 PM EDT
Not listed No phase listed Observational

Study to Examine Insulin Resistance During Growth Hormone Treatment for Short Stature Due to Low Birthweight

NCT00120497
View directory record Official record
Conditions
Fetal Growth Retardation
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 12 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 29, 2026, 5:07 PM EDT
Recruiting Phase 3 Interventional

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

NCT07366086
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Vitamin D, Calcium
Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 19 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 4 Interventional

Sub-Paraspinal Block in Nuss Patients. A Pilot Project

NCT02169297
View directory record Official record
Conditions
Pectus Excavatum, Pain, Postoperative
Interventions
Ultrasound-guided Sub-Paraspinal Block, PCA only
Procedure
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 1 Interventional

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00112853
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
tipifarnib, etoposide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
70 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Oct 29, 2026, 5:07 PM EDT
Not listed No phase listed Observational

Pectus ESC Outcomes and Comparative Effectiveness Study

NCT05063695
View directory record Official record
Conditions
Pectus Excavatum, Pain, Postoperative
Interventions
Multimodal Erector spinae catheter protocol
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 29, 2026, 5:07 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Opioid Sparing Effect of an ISP Nerve Block on Post-Op Pain Control in Posterior Cervical Spine Surgery

NCT06570577
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Inter-semispinalis Plane Block, Opioids
Procedure · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 29, 2026, 5:07 PM EDT
Terminated Phase 2 Interventional Results available

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

NCT01367275
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma
Interventions
Brivanib, Irinotecan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 29, 2026, 5:07 PM EDT
Completed No phase listed Observational

Adipose Tissue and Serum Inflammation in GH Deficiency

NCT03500913
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth Hormone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

NCT05171855
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 81 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Torrance, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 1 Interventional

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

NCT01031368
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cytarabine, clofarabine, filgrastim, Ex-vivo expanded cord blood progenitor cell infusion, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Nohla Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 4 Interventional Results available

Cryoanalgesia vs. Epidural in the Nuss Procedure

NCT02721017
View directory record Official record
Conditions
Pectus Excavatum, Funnel Chest
Interventions
Cryoanalgesia, Thoracic epidural (ropivicaine, fentanyl)
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

NCT04545554
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Romosozumab, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 29, 2026, 5:07 PM EDT
Terminated Phase 4 Interventional

A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury

NCT00638053
View directory record Official record
Conditions
Brain Injuries, Growth Hormone Deficiency Dwarfism
Interventions
somatropin
Genetic
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania • El Paso, Texas • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 29, 2026, 5:07 PM EDT
Completed No phase listed Observational

Trauma Expectation Factor Trauma Outcome Measure

NCT01126398
View directory record Official record
Conditions
Ankle Fracture, Pilon Fracture
Interventions
ankle or distal tibia surgery
Procedure
Lead sponsor
AO Clinical Investigation and Publishing Documentation
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Jacksonville, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 29, 2026, 5:07 PM EDT
Terminated Phase 4 Interventional Results available

Tranexamic Acid for Craniofacial Surgery

NCT00722436
View directory record Official record
Conditions
Craniosynostosis, Bleeding
Interventions
Tranexamic acid, saline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 1 Interventional

Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

NCT00053144
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, irinotecan hydrochloride
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

NCT01811576
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, Recombinant human growth hormone
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
23 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 29, 2026, 5:07 PM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

NCT01861717
View directory record Official record
Conditions
Acromegaly
Interventions
lanreotide
Drug
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 29, 2026, 5:07 PM EDT
Recruiting Early Phase 1 Interventional

Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH

NCT03107520
View directory record Official record
Conditions
Developmental Dysplasia of the Hip
Interventions
Intraoperative contrast-enhanced ultrasound (CEUS), Lumason
Diagnostic Test · Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Months to 24 Months
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 29, 2026, 5:07 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

E-Selectin Nasal Spray to Prevent Stroke Recurrence

NCT00012454
View directory record Official record
Conditions
Cerebrovascular Accident, Transient Ischemic Attack
Interventions
E-Selectin nasal spray
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 29, 2026, 5:07 PM EDT
Completed No phase listed Observational

Genetic Analysis of Fraser Syndrome and Fryns Syndrome

NCT00032877
View directory record Official record
Conditions
Fraser Syndrome, Fryns Syndrome, Chromosomal Abnormalities, Abnormalities, Multiple
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

NCT04085523
View directory record Official record
Conditions
Achondroplasia
Interventions
TransCon CNP, Placebo for TransCon CNP
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 10 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Little Rock, Arkansas • Aurora, Colorado • Saint Paul, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 29, 2026, 5:07 PM EDT
Recruiting Phase 2 Interventional

Oxytocin Effects on Bone in Children With Autism Spectrum Disorder

NCT05754073
View directory record Official record
Conditions
Autism Spectrum Disorder, Bone Health
Interventions
1. Intranasal oxytocin spray, 2. Intranasal placebo spray, 3. Intranasal Oxytocin spray
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
6 Years to 18 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 29, 2026, 5:07 PM EDT